Business Context and Reporting Period
Quoin Pharmaceuticals Ltd. (QNRX) filed a Form 8-K on April 4, 2025, reporting a material modification to the rights of security holders. The company is incorporated in Israel and its American Depositary Shares (ADSs) trade on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a corporate action regarding the company's capital structure.
Material Changes
- Reverse Stock Split: The Board of Directors approved a change in the ADS ratio from 1 ADS representing 1 Ordinary Share to 1 ADS representing 35 Ordinary Shares.
- Effective Date: The 1-for-35 reverse split of issued and outstanding ADSs is effective at the market open on April 9, 2025.
- Shareholder Impact: Holders of uncertificated ADSs in the Direct Registration System (DRS) or Depository Trust Company (DTC) will have the exchange occur automatically. Holders of certificated ADSs must surrender their certificates to the depositary bank.
- Identification: The new CUSIP number for the ADS following the change is 74907L409. The trading symbol remains "QNRX."
Outlook, Risks, and Management Commentary
Purpose: The primary objective of the ratio change is to increase the per-share market price of the ADSs to comply with Nasdaq's $1.00 minimum bid price requirement and maintain the company's listing status.
Risks and Uncertainties: Management explicitly states that while the market price per ADS is expected to increase proportionally, the company provides no assurance that this action will result in satisfying or maintaining the Nasdaq minimum bid price requirement.
Investor Verification Checklist
- Verify the effective date of the reverse split (April 9, 2025) and the new CUSIP number (74907L409).
- Confirm whether holdings are held in certificated form, which requires manual surrender to the depositary bank.
- Monitor the post-split trading price to determine if the company successfully meets the $1.00 minimum bid price requirement.
- Review subsequent filings for any further updates on Nasdaq compliance status.